Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/2468
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | - |
dc.contributor.author | LUNA, Expedito J. A. | - |
dc.contributor.author | FRAZATTI-GALLINA, Neuza M. | - |
dc.contributor.author | TIMENETSKY, Maria C. S. T. | - |
dc.contributor.author | CARDOSO, Maria R. A. | - |
dc.contributor.author | VERAS, Maria A. S. M. | - |
dc.contributor.author | MIRAGLIA, Joao L. | - |
dc.contributor.author | ESCOBAR, Ana M. U. | - |
dc.contributor.author | GRISI, Sandra J. F. E. | - |
dc.contributor.author | RAW, Isaias | - |
dc.contributor.author | PRECIOSO, Alexander R. | - |
dc.date.accessioned | 2013-09-23T17:02:13Z | - |
dc.date.available | 2013-09-23T17:02:13Z | - |
dc.date.issued | 2013 | - |
dc.identifier.citation | VACCINE, v.31, n.7, p.1100-1105, 2013 | - |
dc.identifier.issn | 0264-410X | - |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/2468 | - |
dc.description.abstract | We conducted a phase I, double-blind, placebo-controlled trial to evaluate a new 5-valent oral rotavirus vaccine's safety and immunogenicity profiles. Subjects were randomly assigned to receive 3 orally administered doses of a live-attenuated human-bovine (UK) reassortant rotavirus vaccine, containing five viral antigens (G1, G2, G3, G4 and G9), or a placebo. The frequency and severity of adverse events were assessed. Immunogenicity was evaluated by the titers of anti-rotavirus IgA and the presence of neutralizing antibodies anti-rotavirus. No severe adverse events were observed. There was no difference in the frequency of mild adverse events between experimental and control groups. The proportion of seroconversion was consistently higher in the vaccine group, for all serotypes, after each one of the doses. The 5-valent vaccine has shown a good profile of safety and immunogenicity in this small sample of adult volunteers. | - |
dc.description.sponsorship | Butantan Foundation from BNDES [115/08] | - |
dc.language.iso | eng | - |
dc.publisher | ELSEVIER SCI LTD | - |
dc.relation.ispartof | Vaccine | - |
dc.rights | restrictedAccess | - |
dc.subject | Rotavirus | - |
dc.subject | Vaccine | - |
dc.subject | Clinical trial | - |
dc.subject.other | polymerase chain-reaction | - |
dc.subject.other | safety | - |
dc.subject.other | strains | - |
dc.subject.other | brazil | - |
dc.subject.other | uk | - |
dc.subject.other | immunogenicity | - |
dc.subject.other | candidates | - |
dc.subject.other | efficacy | - |
dc.subject.other | diarrhea | - |
dc.subject.other | children | - |
dc.title | A phase I clinical trial of a new 5-valent rotavirus vaccine | - |
dc.type | article | - |
dc.rights.holder | Copyright ELSEVIER SCI LTD | - |
dc.identifier.doi | 10.1016/j.vaccine.2012.12.020 | - |
dc.identifier.pmid | 23261048 | - |
dc.subject.wos | Immunology | - |
dc.subject.wos | Medicine, Research & Experimental | - |
dc.type.category | original article | - |
dc.type.version | publishedVersion | - |
hcfmusp.author.external | FRAZATTI-GALLINA, Neuza M.:Secretaria Estado Saude Sao Paulo, Inst Butantan, Sao Paulo, Brazil | - |
hcfmusp.author.external | TIMENETSKY, Maria C. S. T.:Secretaria Estado Saude Sao Paulo, Inst Adolfo Lutz, Sao Paulo, Brazil | - |
hcfmusp.author.external | CARDOSO, Maria R. A.:Univ Sao Paulo, Dept Epidemiol, Fac Saude Publ, BR-05508 Sao Paulo, Brazil | - |
hcfmusp.author.external | VERAS, Maria A. S. M.:Fac Ciencias Med Santa Casa Sao Paulo, Sao Paulo, Brazil | - |
hcfmusp.author.external | MIRAGLIA, Joao L.:Secretaria Estado Saude Sao Paulo, Inst Butantan, Sao Paulo, Brazil | - |
hcfmusp.author.external | RAW, Isaias:Secretaria Estado Saude Sao Paulo, Inst Butantan, Sao Paulo, Brazil | - |
hcfmusp.description.beginpage | 1100 | - |
hcfmusp.description.endpage | 1105 | - |
hcfmusp.description.issue | 7 | - |
hcfmusp.description.volume | 31 | - |
hcfmusp.origem | WOS | - |
hcfmusp.origem.id | 2-s2.0-84872618781 | - |
hcfmusp.origem.id | WOS:000314486900015 | - |
hcfmusp.publisher.city | OXFORD | - |
hcfmusp.publisher.country | ENGLAND | - |
hcfmusp.relation.reference | Carvalho-Costa FA, 2011, PEDIATR INFECT DIS J, V30, pS35, DOI 10.1097/INF.0b013e3181fefd5f | - |
hcfmusp.relation.reference | Chandran Aruna, 2010, Biologics, V4, P213 | - |
hcfmusp.relation.reference | Clements-Mann ML, 1999, VACCINE, V17, P2715, DOI 10.1016/S0264-410X(98)00497-6 | - |
hcfmusp.relation.reference | Clements-Mann ML, 2001, VACCINE, V19, P4676, DOI 10.1016/S0264-410X(01)00242-0 | - |
hcfmusp.relation.reference | do Carmo GMI, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001024 | - |
hcfmusp.relation.reference | Eichelberger MC, 2002, J MED VIROL, V66, P407, DOI 10.1002/jmv.2160 | - |
hcfmusp.relation.reference | GENTSCH JR, 1992, J CLIN MICROBIOL, V30, P1365 | - |
hcfmusp.relation.reference | Gomez MM, 2011, J MED VIROL, V83, P1093, DOI 10.1002/jmv.22071 | - |
hcfmusp.relation.reference | GOUVEA V, 1990, J CLIN MICROBIOL, V28, P276 | - |
hcfmusp.relation.reference | Hoshino Y, 1997, J MED VIROL, V51, P319, DOI 10.1002/(SICI)1096-9071(199704)51:4<319::AID-JMV10>3.0.CO;2-D | - |
hcfmusp.relation.reference | Hoshino Y, 2004, J VIROL, V78, P7795, DOI 10.1128/JVI.78.14.7795-7802.2004 | - |
hcfmusp.relation.reference | Nakagomi T, 2008, ARCH VIROL, V153, P591, DOI 10.1007/s00705-007-0028-z | - |
hcfmusp.relation.reference | Parashar UD, 2006, SCIENCE, V312, P851, DOI 10.1126/science.1128827 | - |
hcfmusp.relation.reference | Patel M, 2009, JAMA-J AM MED ASSOC, V301, P2243, DOI 10.1001/jama.2009.756 | - |
hcfmusp.relation.reference | Patel MM, 2011, NEW ENGL J MED, V364, P2283, DOI 10.1056/NEJMoa1012952 | - |
hcfmusp.relation.reference | Richardson V, 2010, NEW ENGL J MED, V362, P299, DOI 10.1056/NEJMoa0905211 | - |
hcfmusp.relation.reference | Ruiz-Palacios GM, 2006, NEW ENGL J MED, V354, P11, DOI 10.1056/NEJMoa052434 | - |
hcfmusp.relation.reference | Soares-Weiser K, 2010, COCHRANE DB SYST REV, P1 | - |
hcfmusp.relation.reference | Timenetsky MCST, 2005, INT C VIR JOINT M 3 | - |
hcfmusp.relation.reference | Vesikari T, 2006, NEW ENGL J MED, V354, P23, DOI 10.1056/NEJMoa052664 | - |
hcfmusp.relation.reference | Ward Richard L, 2008, Ther Clin Risk Manag, V4, P49 | - |
hcfmusp.relation.reference | WHO, 2007, WHO TECH REP SER, V935, P1 | - |
hcfmusp.relation.reference | [Anonymous], 2009, WKLY EPIDEMIOL REC, V84, P220 | - |
dc.description.index | MEDLINE | - |
hcfmusp.remissive.sponsorship | Butantan | - |
hcfmusp.citation.scopus | 17 | - |
hcfmusp.scopus.lastupdate | 2024-03-08 | - |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - FM/MPE Artigos e Materiais de Revistas Científicas - HC/ICr Artigos e Materiais de Revistas Científicas - IMT Artigos e Materiais de Revistas Científicas - LIM/21 Artigos e Materiais de Revistas Científicas - LIM/52 Artigos e Materiais de Revistas Científicas - ODS/03 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_LUNA_A_phase_I_clinical_trial_of_a_new_2013.PDF Restricted Access | publishedVersion (English) | 238.34 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.